Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Phase Distribution

Ph phase_2

75%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

NCT02010242

completedphase_2

GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis

NCT03865927

completedphase_1

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

NCT03740217

completedphase_2

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

NCT03226067

Clinical Trials (4)

Showing 4 of 4 trials

NCT02010242Phase 2

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Completed

NCT03865927Phase 2

GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis

Completed

NCT03740217Phase 1

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

Completed

NCT03226067Phase 2

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4